Case study from RA-BEAM on mTSS analyses
| Model | Base time | Label | Treatment difference at week 24 | P value | Slope estimate |
| ANCOVA+LE | Week=0 | BARI-4mg vs PBO | −0.4890 | <0.0001 | . |
| ANCOVA+LOCF | Week=0 | BARI-4mg vs PBO | −0.4514 | <0.0001 | . |
| RC+obs | Week=0 | BARI-4mg vs PBO | −0.6206 | <0.0001 | −0.026 |
| RC+obs | Week=−3.3 | BARI-4mg vs PBO | −0.5141 | <0.0001 | −0.021 |
| RC+obs | Day=0 | BARI-4mg vs PBO | −0.4894 | <0.0001 | −0.020 |
ANCOVA, analysis of covariance; BARI, baricitinib; LE, linear extrapolation; LOCF, last observation carried forward; obs, observed; PBO, placebo; RA, rheumatoid arthritis; RC, random coefficient.